Bibliographic citations
This is an automatically generated citacion. Modify it if you see fit
Barrera, P., Cattaneo, L., Laguna, L., Ruiz, C. (2023). Business consulting para la empresa Labofarma S.A. [Pontificia Universidad Católica del Perú]. http://hdl.handle.net/20.500.12404/24794
Barrera, P., Cattaneo, L., Laguna, L., Ruiz, C. Business consulting para la empresa Labofarma S.A. []. PE: Pontificia Universidad Católica del Perú; 2023. http://hdl.handle.net/20.500.12404/24794
@mastersthesis{renati/20711,
title = "Business consulting para la empresa Labofarma S.A.",
author = "Ruiz Olivera, Claudia",
publisher = "Pontificia Universidad Católica del Perú",
year = "2023"
}
Title: Business consulting para la empresa Labofarma S.A.
Authors(s): Barrera Pérez, Peter Rolando; Cattaneo Rengifo, Luis Ernesto; Laguna Paz, Larissa Beatriz; Ruiz Olivera, Claudia
Advisor(s): López Orchard, Sergio Andrés
Keywords: Consultores de empresas--Planificación estratégica; Industria farmacéutica--Perú; Comercio internacional--Perú; Control de procesos--Mejoramiento
OCDE field: https://purl.org/pe-repo/ocde/ford#5.02.04
Issue Date: 24-Apr-2023
Institution: Pontificia Universidad Católica del Perú
Abstract: Labofarma S.A. es una empresa farmacéutica de capitales 100% peruanos con casi
medio siglo de experiencia en la elaboración, comercialización y servicio de manufactura de
productos farmacéuticos para el mercado nacional y extranjero. El objetivo de este business
consulting es determinar la solución para el problema clave que es la pérdida de licitaciones
por falta de competitividad en los precios.
Se realizó un análisis del contexto externo e interno utilizando diferentes
herramientas, con el fin conocer la situación real de la empresa, identificando problemas para
corregirlos y áreas de oportunidad para aprovecharlas, es así como se identificaron tres
problemas y a través de una matriz priorización de problemas, se obtuvo como resultado que
el problema principal es que la sección de GV1 al tener un alto costo de producción deja un
margen reducido para ser competitivos en las licitaciones.
Como causa principal se encontró que la automatización de los procesos no está
completa, con dicha información se plantearon y evaluaron las alternativas solución, siendo la
automatización de la línea de acondicionado de la sección de GV1 la que genera mayor
impacto, puesto que al reducir los costos de producción y como consecuencia los precios,
permitirá a Labofarma S.A. tener un mejor posicionamiento de precios para poder ganar una
mayor cantidad de licitaciones.
Siendo que, al ganar una mayor cantidad de licitaciones y tener la capacidad para
cumplir con los tiempos de entrega como efecto de la automatización producirá una dilución
de los costos obteniendo un mayor margen bruto. Es así como, de acuerdo con el análisis
financiero de la implementación se obtiene un VAN de S/ S/ 13,555,883 un TIR de 230%, un
IR de 9.47 un plazo de recuperación de la inversión de 5 meses y 12 días.
Labofarma S.A. is a 100% Peruvian-owned pharmaceutical company with almost half a century of experience in manufacturing, commercialization, and manufacturing services of pharmaceutical products for the domestic and foreign markets. The objective of this business consulting is to determine the solution for the main problem, loss of tenders due to lack of price competitiveness. An analysis of the external and internal context was made using different tools, in order to know the real situation of the company, identifying problems to correct them and areas of opportunity to take advantage of them, so three problems were identified and through a prioritization matrix of problems, it was obtained as a result that the main problem is that the GV1 line to have a high production cost leaves a reduced margin to be competitive in the tenders. As main cause it was found that the automation of the processes is not complete, with this information the solution alternatives were proposed and evaluated, being the automation of the GV1 line the one that generates greater impact, since by reducing the production costs and as a consequence the prices, it will allow Labofarma S.A. to have a better positioning of prices to be able to win a greater number of tenders. By winning a greater number of tenders and having the capacity to comply with delivery times as an effect of automation, it will produce a dilution of costs, obtaining a greater gross margin. Thus, according to the financial analysis of the implementation, an NPV of S/ 13,555,883, an IRR of 230%, an IR of 9.47 and an investment recovery period of 5 months and 12 days are obtained
Labofarma S.A. is a 100% Peruvian-owned pharmaceutical company with almost half a century of experience in manufacturing, commercialization, and manufacturing services of pharmaceutical products for the domestic and foreign markets. The objective of this business consulting is to determine the solution for the main problem, loss of tenders due to lack of price competitiveness. An analysis of the external and internal context was made using different tools, in order to know the real situation of the company, identifying problems to correct them and areas of opportunity to take advantage of them, so three problems were identified and through a prioritization matrix of problems, it was obtained as a result that the main problem is that the GV1 line to have a high production cost leaves a reduced margin to be competitive in the tenders. As main cause it was found that the automation of the processes is not complete, with this information the solution alternatives were proposed and evaluated, being the automation of the GV1 line the one that generates greater impact, since by reducing the production costs and as a consequence the prices, it will allow Labofarma S.A. to have a better positioning of prices to be able to win a greater number of tenders. By winning a greater number of tenders and having the capacity to comply with delivery times as an effect of automation, it will produce a dilution of costs, obtaining a greater gross margin. Thus, according to the financial analysis of the implementation, an NPV of S/ 13,555,883, an IRR of 230%, an IR of 9.47 and an investment recovery period of 5 months and 12 days are obtained
Link to repository: http://hdl.handle.net/20.500.12404/24794
Discipline: Administración Estratégica de Empresas
Grade or title grantor: Pontificia Universidad Católica del Perú. CENTRUM
Grade or title: Maestro en Administración Estratégica de Empresas
Juror: Igor Leopoldo Loza Geldres; Pablo Jose Arana Barbier; Sergio Andres Lopez Orchard
Register date: 24-Apr-2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.